ArticleGastro hep advances2026
Management of Ileal Pouch Cancer in Patients With Inflammatory Bowel Disease.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Histopathologic characterization and clinical associations of ileal pouch polyps in inflammatory bowel disease.Gastroenterology report · 2026Article
- Risk Factors for Pouch Neoplasia in Patients With Inflammatory Bowel Disease: A Case-Control Study.Gastro hep advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Ileal pouch cancer in patients with inflammatory bowel disease, though rare, represents a significant concern due to the high mortality. While prior studies emphasized incidence and risk factors, this study evaluates the current management and prognosis of pouch cancer following ileal pouch-anal anastomosis. Methods: Consecutive patients with pouch cancer were identified from a prospectively maintained database (2019-2025). Patients with familial adenomatous polyposis and precancerous conditions were excluded. Demographic, clinical, endoscopic, and histologic data were collected. Primary outcomes were disease recurrence/progression and oncological survival. Results: Of 699 patients, 10 developed pouch cancer (incidence: 0.5 per 100 person-years). Lesions were located at the cuff (n = 3), anal transition zone (n = 3), pouch body (n = 2), prepouch ileum (n = 1), and both anal transition zone and pouch body (n = 1). Two patients presented with distant metastases without endoscopically visible lesions in the pouch. The histological types were adenocarcinoma (n = 5), squamous cell carcinoma (n = 3), non-Hodgkin lymphoma (n = 1), and neuroendocrine tumor (n = 1). The diagnosis was established through endoscopic biopsies (n = 2), surgical resection (n = 6; three with prior endoscopically diagnosed dysplasia), and cross-sectional imaging (n = 2). Seven patients had localized disease, allowing curative treatment. Treatments included surgery (n = 5), chemoradiotherapy (n = 6), and lanreotide for neuroendocrine tumor. Over a median follow-up of 2.8 years (interquartile range: 1.5-5.2), recurrence or disease progression occurred in three patients (30%), and one patient (10%) died from pouch cancer, with a 5-year cumulative survival of 88.9%. Conclusion: Adenocarcinoma remains the most common histological type; however, nonadenocarcinoma, especially the squamous cell carcinoma, has been increasingly recognized. Endoscopic surveillance was helpful in detecting precancerous lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.